Image Source: UnsplashAn IntroductionOf the 10 clinical-stage AI-focused (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced and they are now down 21.6%, on average, YTD.This article presents their stock performances this week, in descending order, and MTD, and their areas of focus, along with their latest news, analyses and commentary where available.Before proceeding, read Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here’s What You Need to Know to understand why psychedelic stocks are in decline.
- reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Latest news, commentary and/or analysis:
- Wall Street Analysts Think Exscientia Still Has a 54.5% Upside From Friday’s Close – Here’s Why
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- None
- focuses on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder
- has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Latest news, commentary and/or analysis:
- None
- focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Latest news, commentary and/or analysis:
- MindMed Has Constructive Meeting with FDA for MM120 on Generalized Anxiety Disorder
- specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Latest news, commentary and/or analysis:
- None
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest news, commentary and/or analysis:
- Should You Buy the Dip on Compass Pathways Stock?
- develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Latest news, commentary and/or analysis:
- Is AbCellera Biologics a Buy on the Dip?
- specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Latest news, commentary and/or analysis:
- None
- focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Latest news, commentary and/or analysis:
- Is Absci the Best Debt-Free (Halal) Stock According to Hedge Funds?
SummaryOn average, the above 10 stocks were down 6.0% last week, on average, are down 10.9% MTD and are now down 21.6% YTD. The 4 constituents in the Psychedelic Compound-based Drug Stocks Portfolio were down 3.9%, on average, this week and are down 16.2%, on average, MTD while the 6 constituents in the AI-focused Drug Discovery Stocks Portfolio were 7.2%, on average, this week and are down 7.6%, on average, MTD.More By This Author:Aurora Cannabis Q4 Financials Continue To Disappoint: Stock Declines
Micro/Small Cap AI Stocks Portfolio Has Tumbled 9.5% So Far This June
The 6 Segments Of The Semiconductor Value Chain Now Up 31% YTD
